🇺🇸 FDA
Pipeline program

ALD518

ALD518-CLIN-009

Phase 2 mab terminated

Quick answer

ALD518 for Oral Mucositis is a Phase 2 program (mab) at CSL Behring GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
CSL Behring GmbH
Indication
Oral Mucositis
Phase
Phase 2
Modality
mab
Status
terminated

Clinical trials